A Myeloma Screen includes the following tests: serum protein electrophoresis, total protein, albumin, total immunoglobulins and serum free light chain analysis.
Protein electrophoresis alone is not considered an adequate screen for monoclonal gammopathies.
Plasma samples are NOT acceptable, as the presence of a fibrinogen band may be confused for a monoclonal band.
Ambient (8 - 24 degrees Celsius)
An interpretive comment is provided with the report.
If a monoclonal band is detected, immunofixation will be performed to identify the abnormal immunoglobulins involved. The monoclonal band will be quantitated by densitometric scanning of the gel using the perpendicular drop gating method.
A qualitatively normal but elevated gamma fraction (polyclonal increase in immunoglobulins) is consistent with infection, liver disease, or autoimmune disease.
Decreased immunoglobulins (hypogammaglobulinaemia) is consistent with immune deficiency and can also be associated with primary amyloidosis or nephrotic syndrome.
An absent or reduced alpha-1 fraction is consistent with alpha-1 antitrypsin deficiency and further testing will be suggested if clinically indicated.
A raised alpha-1 and or alpha-2 fraction are indication of a recent or current inflammatory process.
A low alpha-2 fraction can be indicative of haemolysis or liver disease. Haptoglobin testing is added if this is noted.
|Monoclonal Band Size||Uncertainty of Measurement|
|< 10 g/L||20 %|
|10 – 20 g/L||8 %|
|> 20 g/L||4 %|
|Beta migrating M Bands||20 %|
MYELOMA SCREEN includes the following tests:
Serum Protein Electrophoresis
Immunoglobulin Quantitation (IgG, IgA, IgM)
Serum Free Light Chains
Contact Canterbury Health Laboratories on +64 3 364 0484 or email LabInfo@cdhb.health.nz
Each test component will be charged individually.